RESEARCH MONOGRAPH · KDC-MN-282

Triptorelin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

81/100

Clinically-mature GnRH agonist with decades of oncology and reproductive data, often overlooked outside its main indications

Triptorelin is one of those compounds where the clinical depth is way deeper than the research-supplier conversation reflects. It's been on the market since the late 80s under Decapeptyl, Trelstar, Pamorelin, depending on the geography. The mechanism is textbook GnRH agonism: continuous receptor occupancy initially triggers a flare in LH and FSH, then desensitizes the pituitary gonadotrophs and you get sustained suppression of the gonadal axis. The flare phase is the part that matters mechanistically and the part most casual descriptions skip.

The evidence base is genuinely strong. Prostate cancer (androgen deprivation), central precocious puberty, endometriosis, uterine fibroids, assisted reproduction protocols. Multiple phase 3 trials, decades of post-marketing data, and reasonably consistent pharmacology across formulations (the depot vs immediate-release distinction matters more than people think for what kind of suppression curve you actually get).

What's interesting from a research perspective: triptorelin has been used in single-dose protocols specifically to exploit the flare, not the suppression. The downstream LH spike is reproducible enough that it shows up in fertility research as a trigger agent. That's a totally different use case from chronic suppression and the literature on it is solid.

Sourcing is where things get more interesting. The pharma-grade product is well-characterized, but research-grade triptorelin acetate from peptide suppliers varies more than you'd expect for a 10-residue peptide. The pGlu N-terminus and the D-Trp at position 6 are both modifications that have to land correctly for receptor binding, and not every supplier QCs cleanly for those. HPLC purity numbers above 98 percent are achievable but check the certificate.

What we dont love is how triptorelin gets conflated with leuprolide in research discussions. They're different decapeptides with different pharmacokinetics. Triptorelin has a longer terminal half-life than people assume, and the depot formulations are not interchangeable.

Worth having on the shelf for any GnRH-axis research? yeah, easily. The mechanism is well-mapped, the clinical literature is deep, and the compound is reliable when sourced from a vendor that actually QCs the D-Trp. Honestly underrated outside its primary clinical lanes.

Evidence: 90
Mechanism: 92
Reliability: 85
Safety: 80
Sourcing: 75
Value: 70
Signal: 70
Staying power: 85

Plain-language summary Intrigue 55 / 100

Triptorelin (Trelstar) is a synthetic 10-amino-acid GnRH agonist used in long-acting depot form for prostate cancer, endometriosis, and precocious puberty. The pharmacology has a counterintuitive twist: continuous (rather than the normal pulsatile) GnRH receptor stimulation initially causes a flare in testosterone or estrogen, then desensitizes and downregulates the receptor over one to two weeks, producing sustained suppression. So a drug that activates the GnRH system ends up shutting down sex hormone production. The depot formulations release peptide over one, three, or six months. In bodybuilding circles a single-shot dose has been used (anecdotally and unwisely) as post-cycle therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist decapeptide used for paradoxical HPG suppression in prostate cancer, endometriosis, and precocious puberty.

Abstract

Triptorelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; CAS 57773-63-4; molecular formula C64H82N18O13; molecular weight 1311.45) is a synthetic GnRH (LHRH) agonist decapeptide developed in the 1970s and approved by the FDA in 2000 (Trelstar). Mechanism: continuous occupation of pituitary GnRH receptors initially produces a flare in LH, FSH, and consequent sex hormone secretion (1 to 2 weeks); chronic exposure desensitizes and downregulates GnRH receptors, producing a sustained reduction in LH and FSH and, downstream, in testosterone (men) and estradiol (women). Plasma half-life of the parent peptide is approximately 3 hours; depot formulations release peptide over 1, 3, or 6 months for sustained suppression. Approved indications include locally advanced and metastatic prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. The flare period in prostate cancer is mitigated by concurrent androgen receptor antagonist (bicalutamide). Used as a reference GnRH agonist in academic endocrine pharmacology.

Mechanism of action

GnRH agonist decapeptide; chronic exposure desensitizes pituitary GnRH receptors and suppresses LH/FSH and consequent sex hormones. Initial flare followed by sustained suppression.

Reported research dose ranges

Clinical depot 3.75 mg, 11.25 mg three-monthly, or 22.5 mg intramuscular. Rodent studies 0.1 to 1 mg/kg.

References

Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs Aging 1994.
Heyns CF, et al. A randomised comparison of triptorelin pamoate and goserelin acetate. Eur Urol 2003.
Eisenberger MA, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-282

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Triptorelin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs